Compare OI & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OI | STOK |
|---|---|---|
| Founded | 1903 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 1994 | 2019 |
| Metric | OI | STOK |
|---|---|---|
| Price | $10.41 | $30.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | $17.57 | ★ $36.80 |
| AVG Volume (30 Days) | ★ 2.2M | 690.8K |
| Earning Date | 04-28-2026 | 03-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.73 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,426,000,000.00 | $184,420,000.00 |
| Revenue This Year | $3.07 | N/A |
| Revenue Next Year | $1.83 | $74.28 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 404.50 |
| 52 Week Low | $9.23 | $5.35 |
| 52 Week High | $16.91 | $40.22 |
| Indicator | OI | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 24.09 | 39.74 |
| Support Level | N/A | $20.33 |
| Resistance Level | $13.46 | $35.75 |
| Average True Range (ATR) | 0.53 | 2.40 |
| MACD | -0.15 | -0.65 |
| Stochastic Oscillator | 1.03 | 4.24 |
O-I Glass is the world's largest manufacturer of glass bottles; 70% of its revenue comes from outside the United States. O-I has a leading position in key markets such as Europe, North America, and Brazil. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food. O-I is looking to maintain or expand its dominant positions in Europe, North America, and South America.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.